Webcast ImageWebcast
CTI BioPharma Corp at 27th Annual Piper Jaffray Healthcare Conference (Live)
12/02/15 at 12:00 p.m. ET

CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contacts

  • Current Quote
  • Stock Chart
$1.20 - 0.05 (4.00%)
Day High:$1.28
Day Low:$1.20
11/27/151:00 p.m. ET
Delayed at least 15 minutes.

Monique Greer
T +1 206-272-4343
Ed Bell
T +1 206-272-4345


Recent News

Nov 24, 2015CTI BioPharma Announces United Kingdom National Cancer Research Institute AML Cooperative Group Advances Tosedostat to Next Stage of "Pick-a-Winner" LI-1 Trial for Older Patients with AML or High-Risk MDS
SEATTLE, Nov. 24, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma or the Company) (NASDAQ and MTA: CTIC) today announced that the United Kingdom's National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group has chosen to advance tosedostat, the Company's investigative oral aminopeptidase inhibitor, to the second stage of a randomized clinical trial of low-dose cytarabine plus or minus tosedostat in older patients with Acute Myeloid Leukemia (AML) or high risk... 
Printer Friendly Version
Nov 24, 2015CTI BioPharma to Present at 27th Annual Piper Jaffray Healthcare Conference
SEATTLE, Nov. 24, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that management will present at the 27th Annual Piper Jaffray Healthcare Conference on Wednesday, December 2, 2015, at 12:00 p.m. EST/6:00 p.m. CET in New York. The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at About CTI BioPharma CTI BioPharma Corp. (NASDAQ and MTA: CTIC) is a biopharmaceutical c... 
Printer Friendly Version
Nov 23, 2015CTI BioPharma Initiates Rolling Submission of U.S. New Drug Application for Pacritinib for the Treatment of Patients with Myelofibrosis
-- Completion of NDA Submission Expected Before the End of 2015 -- SEATTLE, Nov. 23, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) announced the initiation of its rolling new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. As part of the application, CTI BioPharma and its partner, Baxalta Incorporated (Baxalta), are seeking accele... 
Printer Friendly Version


Nov 05, 2015
Q3 2015 CTI BioPharma Corp Earnings Conference Call
Sep 29, 2015
CTI BioPharma Corp at Ladenburg Thalmann 2015 Healthcare Conference
Data provided by Nasdaq. Minimum 15 minutes delayed.